Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

Area of Science:

• Oncology
• Immunotherapy

Background:

• Seven immune checkpoint inhibitors (ICIs) are approved for cancer treatment, offering durable responses in some patients.
• A subset of patients treated with ICIs develop hyperprogressive disease (HPD), characterized by accelerated tumor growth.
• HPD is associated with significantly worse patient outcomes compared to standard progression or resistance.

Purpose of the Study:

• To review the phenomenon of hyperprogressive disease in cancer patients treated with immune checkpoint inhibitors.
• To discuss the current understanding, diagnostic criteria, and potential genomic correlates of HPD.
• To highlight the need for further research into the mechanisms underlying HPD.

Main Methods:

• Review of existing literature and clinical observations regarding hyperprogressive disease.
• Discussion of commonly used criteria for defining HPD (e.g., time to treatment failure < 2 months, twofold increase in progression rate).
• Exploration of suggested, yet unvalidated, genomic correlates such as MDM2 amplification and EGFR mutations.

Main Results:

• Hyperprogressive disease represents a paradoxical acceleration of tumor growth in a minority of patients receiving ICIs.
• While consensus criteria are lacking, HPD is often defined by rapid treatment failure and a significant increase in tumor progression rate.
• Observed increases in progression rate can be dramatic, reaching 35- to 40-fold in some cases.

Conclusions:

• Hyperprogressive disease is a recognized, albeit debated, phenomenon in cancer immunotherapy.
• Understanding the mechanisms driving HPD and identifying reliable predictive biomarkers are critical unmet needs.
• Further investigation is urgently warranted to elucidate the underlying biology and improve patient management.